Abstract 5144
Background
Ever since the “seed-and-soil” hypothesis, the mechanism of cancer metastatic organotropism is still an unsolved mystery. In colorectal cancer (CRC), there is still no robust metastasis predictive biomarkers for distant organ metastasis, which is the most common cause of deaths. In spite of the function of exosome in RNA and protein delivery, its clinical significance in CRC metastasis remains uncertain. Here, we evaluated the potential role of serum exosome integrin in CRC metastasis.
Methods
Tissue integrin αvβ5 was quantified by quantitative reverse-transcription PCR in 31 pairs of primary CRC and corresponding matched liver metastasis (LM), with non-LM as control. Serum exosomal integrin αvβ5 was accessed by ELISA in 126 CRC patients with LM and 166 CRC patients without, as well as when LM was diagnosed in these 166 patients in exploratory cohort. In prospective validation cohort, serum exosomal integrin αvβ5 was investigated in 135 initially diagnosed CRC patients without metastasis. CRC-associated metastasis mouse models were established to verify the role of serum exosomal integrin αvβ5.
Results
Integrin αvβ5 level in LM was significantly increased compared with that in non-LM, which was correlated with its expression in primary CRC. Serum exosomal integrin αvβ5 was significantly increased in CRC patients with LM than those without, in a TNM stage-dependent manner. Moreover, it was found that serum exosomal integrin αvβ5 in CRC patients was significantly upregulated when LM occurred and associated with unfavorable survival. In validation cohort, increased serum exosomal integrin αvβ5 indicated higher risk of LM and unfavorable prognosis. Serum exosomal integrin αvβ5 was significantly increased in mice with LM compared with controls.
Conclusions
Our clinical and animal model data indicate that increased levels of serum integrin αvβ5 associate with CRC LM and unfavorable survival. These results suggested that circulating integrin αvβ5 could be a promising non-invasive predictor for CRC LM and prognosis.
Clinical trial identification
Legal entity responsible for the study
Xi'an Jiaotong University.
Funding
NSFC.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract